Inflectra and Campylobacter infection - a phase IV clinical study of FDA data

Summary:

Campylobacter infection is reported as a side effect among people who take Inflectra (infliximab-dyyb), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Prednisone, and have Ulcerative colitis.

The phase IV clinical study analyzes which people have Campylobacter infection when taking Inflectra. It is created by eHealthMe based on reports of 52,342 people who have side effects when taking Inflectra from the FDA, and is updated regularly.

What is Inflectra?

Inflectra has active ingredients of infliximab-dyyb. eHealthMe is studying from 52,370 Inflectra users. Check the latest studies of Inflectra.

What is Campylobacter infection?

Campylobacter infection (infection by the campylobacter bacterium) is found to be associated with 126 drugs and 357 conditions by eHealthMe. Check the latest studies of Campylobacter infection.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 31, 2026

52,342 people reported to have side effects when taking Inflectra.
Among them, 18 people (0.03%) have Campylobacter infection.

Could Inflectra cause Campylobacter infection?

Among these 18 people:

How long have people been on Inflectra when they have Campylobacter infection? *

  • < 1 month: 20 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 80 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Campylobacter infection when taking Inflectra? *

  • female: 66.67 %
  • male: 33.33 %

What is the age of people who have Campylobacter infection when taking Inflectra? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

What are other drugs people take besides Inflectra? *

  1. Prednisone: 7 people, 38.89%
  2. Solu-Medrol: 4 people, 22.22%
  3. Methotrexate: 4 people, 22.22%
  4. Folic Acid: 4 people, 22.22%
  5. Pentasa: 3 people, 16.67%
  6. Pantoprazole: 3 people, 16.67%
  7. Hydroxychloroquine Sulfate: 3 people, 16.67%
  8. Symbicort: 2 people, 11.11%
  9. Singulair: 2 people, 11.11%
  10. Alvesco: 2 people, 11.11%

What are other side effects people have besides Campylobacter infection? *

  1. Malaise (a feeling of general discomfort or uneasiness): 7 people, 38.89%
  2. Dizziness: 5 people, 27.78%
  3. Rhinorrhea (watery mucus discharge from the nose): 5 people, 27.78%
  4. Nasopharyngitis (inflammation of the nasopharynx): 5 people, 27.78%
  5. Joint Pain: 5 people, 27.78%
  6. Blood Pressure Fluctuation: 4 people, 22.22%
  7. Respiratory Tract Infection: 4 people, 22.22%
  8. Itching: 4 people, 22.22%
  9. Gallstones (stone formation by bile component): 3 people, 16.67%
  10. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 16.67%

What are the existing conditions these people have? *

  1. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 9 people, 50.00%
  2. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 6 people, 33.33%
  3. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 16.67%
  4. Sleep Disorder: 1 person, 5.56%
  5. Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 1 person, 5.56%
  6. Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 5.56%
  7. Diarrhea: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Inflectra and have Campylobacter infection?

- Check whether Campylobacter infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Inflectra:

Campylobacter infection treatments and more:

How severe was Campylobacter infection and when was it recovered:

Expand to all the drugs that have ingredients of infliximab-dyyb:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Inflectra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Campylobacter infection:

Browse all the conditions that are associated with Campylobacter infection:


How the study uses the data?

The study uses data from the FDA. It is based on infliximab-dyyb (the active ingredients of Inflectra) and Inflectra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: